​

CRISPR Therapeutics (CRSP) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChart

CRISPR Therapeutics Revenue Highlights

Latest Revenue (Y)

$37.31M

Latest Revenue (Q)

$602.00K

Main Segment (Y)

Collaboration Revenue

CRISPR Therapeutics Revenue by Period

CRISPR Therapeutics Revenue by Year

DateRevenueChange
2024-12-31$37.31M-89.95%
2023-12-31$371.21M85038.99%
2022-12-31$436.00K-99.95%
2021-12-31$913.08M168054.88%
2020-12-31$543.00K-99.81%
2019-12-31$289.59M9169.85%
2018-12-31$3.12M-92.38%
2017-12-31$41.00M693.90%
2016-12-31$5.16M1990.69%
2015-12-31$247.00K100.00%
2014-12-31--

CRISPR Therapeutics generated $37.31M in revenue during NA 2024, up -89.95% compared to the previous quarter, and up 12.89% compared to the same period a year ago.

CRISPR Therapeutics Revenue by Quarter

DateRevenueChange
2024-09-30$602.00K16.44%
2024-06-30$517.00K2.58%
2024-03-31$504.00K-99.75%
2023-12-31$200.00M100.00%
2023-09-30--100.00%
2023-06-30$70.00M-30.00%
2023-03-31$100.00M1666566.67%
2022-12-31$6.00K-93.62%
2022-09-30$94.00K-40.51%
2022-06-30$158.00K-11.24%
2022-03-31$178.00K-98.56%
2021-12-31$12.35M3653.19%
2021-09-30$329.00K-99.96%
2021-06-30$900.20M445544.55%
2021-03-31$202.00K4.12%
2020-12-31$194.00K31.08%
2020-09-30$148.00K236.36%
2020-06-30$44.00K-71.97%
2020-03-31$157.00K-99.80%
2019-12-31$77.02M-63.66%
2019-09-30$211.93M66544.03%
2019-06-30$318.00K-3.05%
2019-03-31$328.00K185.22%
2018-12-31$115.00K-79.57%
2018-09-30$563.00K-48.25%
2018-06-30$1.09M-19.88%
2018-03-31$1.36M-95.80%
2017-12-31$32.33M1254.21%
2017-09-30$2.39M-33.36%
2017-06-30$3.58M32.52%
2017-03-31$2.70M15.32%
2016-12-31$2.34M51.32%
2016-09-30$1.55M94.84%
2016-06-30$795.00K67.02%
2016-03-31$476.00K92.71%
2015-12-31$247.00K100.00%
2015-09-30--

CRISPR Therapeutics generated $602.00K in revenue during Q3 2024, up 16.44% compared to the previous quarter, and up 0.86% compared to the same period a year ago.

CRISPR Therapeutics Revenue Breakdown

CRISPR Therapeutics Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 24Dec 23Dec 22Dec 21Dec 20
Collaboration Revenue$35.00M$370.00M$436.00K--
Grant$2.31M$1.21M$762.00K--
Duchenne Muscular Dystrophy License---$151.10M$151.10M
Myotonic Dystrophy Type One R And D Services---$1.10M$1.10M
Specified Target Option Material Right---$11.80M$11.80M
Exclusive License---$900.00M-
Myotonic Dystrophy Type One License---$51.30M$51.30M
Collaborative Arrangement Material Rights Fourth Exclusive License---$6.70M-
Collaborative Arrangement Material Rights---$46.70M$46.70M

CRISPR Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 24: Collaboration Revenue (93.80%), and Grant (6.20%).

Quarterly Revenue by Product

Product/ServiceDec 24Sep 24Jun 24Mar 24Dec 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Sep 20Jun 20Mar 20Jun 19Mar 19
Grant$691.00K$602.00K$517.00K$504.00K-----$762.00K$551.00K---------
Collaboration Revenue----$200.00M$70.00M$100.00M$6.00K$94.00K$158.00K$178.00K$12.35M--------
Duchenne Muscular Dystrophy License------------$151.10M$151.10M$151.10M$151.10M$151.10M$151.10M--
Myotonic Dystrophy Type One R And D Services------------$1.10M$1.10M$1.10M$1.10M$1.10M$1.10M--
Collaborative Arrangement Material Rights------------$46.70M$46.70M$46.70M$46.70M$46.70M$46.70M--
Specified Target Option Material Right------------$11.80M$11.80M$11.80M$11.80M$11.80M$11.80M--
Myotonic Dystrophy Type One License------------$51.30M$51.30M$51.30M$51.30M$51.30M$51.30M--
License And Service------------------$100.00K$100.00K

CRISPR Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Dec 24: Grant (100.00%).

CRISPR Therapeutics Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
NVONovo Nordisk$232.26B$65.35B
REGNRegeneron Pharmaceuticals$14.20B$3.72B
SRPTSarepta Therapeutics$1.90B$362.93M
KRYSKrystal Biotech$290.51M$83.84M
CRSPCRISPR Therapeutics$37.31M$602.00K
VERVVerve Therapeutics$32.33M$6.87M
FATEFate Therapeutics$13.63M$6.77M
NTLAIntellia Therapeutics-$9.11M
EDITEditas Medicine--
RAINRain Enhancement Technologies Holdco--
HEPAHepion Pharmaceuticals--
CRBUCaribou Biosciences-$3.46M
BEAMBeam Therapeutics-$14.27M

CRSP Revenue FAQ

What is CRISPR Therapeutics’s yearly revenue?

CRISPR Therapeutics's yearly revenue for 2024 was $37.31M, representing a decrease of -89.95% compared to 2023. The company's yearly revenue for 2023 was $371.21M, representing an increase of 85038.99% compared to 2022. CRSP's yearly revenue for 2022 was $436K, representing a decrease of -99.95% compared to 2021.

What is CRISPR Therapeutics’s quarterly revenue?

CRISPR Therapeutics's quarterly revenue for Q3 2024 was $602K, a 16.44% increase from the previous quarter (Q2 2024), and a 0% increase year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $517K, a 2.58% increase from the previous quarter (Q1 2024), and a -99.26% decrease year-over-year (Q2 2023). CRSP's quarterly revenue for Q1 2024 was $504K, a -99.75% decrease from the previous quarter (Q4 2023), and a -99.50% decrease year-over-year (Q1 2023).

What is CRISPR Therapeutics’s revenue growth rate?

CRISPR Therapeutics's revenue growth rate for the last 3 years (2022-2024) was 8458.26%, and for the last 5 years (2020-2024) was 6771.82%.

What are CRISPR Therapeutics’s revenue streams?

CRISPR Therapeutics's revenue streams in c 24 are Collaboration Revenue, and Grant. Collaboration Revenue generated $35M in revenue, accounting 93.80% of the company's total revenue, down -90.54% year-over-year. Grant generated $2.31M in revenue, accounting 6.20% of the company's total revenue, up 91.87% year-over-year.

What is CRISPR Therapeutics’s main source of revenue?

For the fiscal year ending Dec 24, the largest source of revenue of CRISPR Therapeutics was Collaboration Revenue. This segment made a revenue of $35M, representing 93.80% of the company's total revenue.